CRI’s Response to NIH Cuts with Alicia Zhou, Ph.D.
Failed to add items
Add to Cart failed.
Add to Wish List failed.
Remove from wishlist failed.
Adding to library failed
Follow podcast failed
Unfollow podcast failed
CRI’s Response to NIH Cuts with Alicia Zhou, Ph.D.
-
Narrated by:
-
By:
About this listen
We love to hear from our listeners. Send us a message.
In this episode of the Cell & Gene podcast, Host Erin Harris speaks with Alicia Zhou, Ph.D., CEO of the Cancer Research Institute (CRI), about CRI’s mission to advance cancer immunotherapy and the critical role of federal funding, particularly from the NIH, in supporting basic and translational cancer research. Dr. Zhou highlights CRI’s focus on funding early-stage science and clinical trials to move immunotherapy toward curing all cancers. She covers the serious implications of recent U.S. Government funding cuts, including NIH budget freezes and halted grant review processes, which are already impacting biomedical research institutions, graduate programs, and clinical trials. In light of the NIH budget cuts, Dr. Zhou explains how CRI is stepping up by committing an additional $2.5 million from its reserves to fund 10 postdoctoral fellowships.
Subscribe to the podcast!
Apple | Spotify | YouTube